(Q35098736)

6 August 2017

1 reference

title

Medical management of prolactin-secreting pituitary adenomas (English)

1 reference

6 August 2017

Mark E Molitch

1

1 reference

6 August 2017

1 January 2002

1 reference

6 August 2017

1 reference

6 August 2017

5

1 reference

6 August 2017

2

1 reference

6 August 2017

55-65

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1022375429083

6 August 2017

0 references

cites work

Late development of resistance to bromocriptine in a patient with macroprolactinoma

1 reference

12 December 2020

Antipsychotic drug-induced hyperprolactinemia: clinical implications

1 reference

12 December 2020

The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma

1 reference

12 December 2020

Cabergoline in the long-term therapy of hyperprolactinemic disorders.

1 reference

12 December 2020

Growth-hormone and prolactin excess.

1 reference

12 December 2020

Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage

1 reference

12 December 2020

Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment

1 reference

12 December 2020

Psychotic reactions during treatment of pituitary tumours with dopamine agonists

1 reference

12 December 2020

Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone

1 reference

12 December 2020

Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenoma size

1 reference

12 December 2020

Treatment of macroprolactinoma with cabergoline: a study of 85 patients

1 reference

12 December 2020

Changes in computed tomographic findings in microprolactinomas before and after bromocriptine

1 reference

12 December 2020

Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy

1 reference

12 December 2020

Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal

1 reference

12 December 2020

Neurogenic Galactorrhea-Amenorrhea*

1 reference

12 December 2020

Serum prolactin levels in untreated primary hypothyroldism

1 reference

12 December 2020

The natural history of idiopathic hyperprolactinemia.

1 reference

12 December 2020

Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size

1 reference

12 December 2020

The Efficacy and Tolerability of CV 205–502 (a Nonergot Dopaminergic Drug) in Macroprolactinoma Patients and in Prolactinoma Patients Intolerant to Bromocriptine

1 reference

12 December 2020

Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.

1 reference

12 December 2020

Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia

1 reference

12 December 2020

Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma

1 reference

12 December 2020

Dopamine agonists and pituitary tumor shrinkage

1 reference

12 December 2020

Serum prolactin in liver disease and its relationship to gynaecomastia

1 reference

12 December 2020

Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function

1 reference

12 December 2020

CV 205-502 treatment of hyperprolactinemia

1 reference

12 December 2020

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

12 December 2020

High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas

1 reference

12 December 2020

Hyperprolactinemia. Long-term effects of bromocriptine

1 reference

12 December 2020

Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency.

1 reference

12 December 2020

Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

1 reference

12 December 2020

A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia

1 reference

12 December 2020

Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia

1 reference

12 December 2020

Pregnancy in hyperprolactinemic women

1 reference

12 December 2020

Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics

1 reference

12 December 2020

Pergolide as primary therapy for macroprolactinomas

1 reference

12 December 2020

Prolactinoma in wall of ovarian dermoid cyst with hyperprolactinemia.

1 reference

12 December 2020

Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas

1 reference

12 December 2020

Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration

1 reference

12 December 2020

Enlargement of a prolactin-secreting pituitary microadenoma during bromocriptine treatment. Case report

1 reference

12 December 2020

Pituitary carcinoma: a clinicopathologic study of 15 cases

1 reference

12 December 2020

Verapamil-induced hyperprolactinemia and galactorrhea

1 reference

12 December 2020

Rapid Changes of Prolactinoma Volume after Withdrawal and Reinstitution of Bromocriptine*

1 reference

12 December 2020

Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones

1 reference

12 December 2020

Outcome of pregnancies in women with treated or untreated hyperprolactinemia

1 reference

12 December 2020

Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy

1 reference

12 December 2020

Relationship between maternal prolactin levels during pregnancy and lactation in women with pituitary adenoma

1 reference

12 December 2020

Vaginal bromocriptine in hyperprolactinemic patients and puerperal women

1 reference

12 December 2020

Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas.

1 reference

12 December 2020

DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.

1 reference

12 December 2020

Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy

1 reference

12 December 2020

Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography

1 reference

12 December 2020

Reduction in size of prolactin-secreting tumours in men treated with pergolide

1 reference

12 December 2020

Elevation of plasma-prolactin by monoamine-oxidase inhibitors

1 reference

12 December 2020

Long-term follow-up of hyperprolactinemic women treated with bromocriptine.

1 reference

12 December 2020

Perivascular fibrosis in prolactinomas: is it increased by bromocriptine?

1 reference

12 December 2020

Visual loss in pregnant women with pituitary adenomas

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers

1 reference

12 December 2020

Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience

1 reference

12 December 2020

Role of radiation therapy in clinical hormonally-active pituitary adenomas

1 reference

12 December 2020

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

1 reference

12 December 2020

Follow-up of children born of bromocriptine-treated mothers

1 reference

12 December 2020

Gamma knife radiosurgery for prolactinomas

1 reference

12 December 2020

Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases

1 reference

12 December 2020

Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.

1 reference

12 December 2020

Short-term preoperative treatment of macroprolactinomas by dopamine agonists

1 reference

12 December 2020

Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal

1 reference

12 December 2020

Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502

1 reference

12 December 2020

Effects of methyldopa on prolactin and growth hormone

1 reference

12 December 2020

1 reference

12 December 2020

Reversible galactorrhea and prolactin elevation related to fluoxetine use.

1 reference

12 December 2020

Bromocriptine in pregnancy: safety aspects

1 reference

12 December 2020

1 reference

12 December 2020

Prolactin-producing microadenomas in pregnancy

1 reference

12 December 2020

Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia

1 reference

12 December 2020

Long-term treatment of prolactin-secreting macroadenomas with pergolide

1 reference

12 December 2020

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine

1 reference

12 December 2020

Pregnancy outcome after treatment with the ergot derivative, cabergoline.

1 reference

12 December 2020

Is prolactin secreted ectopically?

1 reference

12 December 2020

The natural history of untreated hyperprolactinemia: a prospective analysis

1 reference

12 December 2020

In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine

1 reference

12 December 2020

Management of extra-sellar pituitary tumours with bromocriptine: comparison of prolactin secreting and non-functioning tumours using half-field visual evoked potentials and computerised tomography

1 reference

12 December 2020

The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia.

1 reference

12 December 2020

Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study

1 reference

12 December 2020

Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients

1 reference

12 December 2020

Pituitary incidentalomas

1 reference

12 December 2020

Resistance to bromocriptine in prolactinomas

1 reference

12 December 2020

Current approaches to imaging of the sellar region and pituitary

1 reference

12 December 2020

Pregnancy and the hyperprolactinemic woman

1 reference

12 December 2020

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

12 December 2020

Surgery during pregnancy and fetal outcome.

1 reference

12 December 2020

Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline

1 reference

12 December 2020

Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors

1 reference

12 December 2020

Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging

1 reference

12 December 2020

Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement

1 reference

12 December 2020

Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report

1 reference

12 December 2020

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

12 December 2020

A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic admknistration of bromocriptine

1 reference

12 December 2020

Two-year treatment with oral contraceptives in hyperprolactinemic patients.

1 reference

12 December 2020

Serum prolactin concentration in patients taking neuroleptic drugs

1 reference

12 December 2020

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients

1 reference

12 December 2020

Pregnancy outcome after cabergoline treatment in early weeks of gestation

1 reference

12 December 2020

Bromocriptine as prophylactic therapy in prolactinoma during pregnancy

1 reference

12 December 2020

The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases

1 reference

12 December 2020

Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1022375429083

1 reference

PubMed ID

12675502

Dimensions Publication ID

6 August 2017

0 references

1 reference

PubMed ID

12675502